Objectives: High-dose pelvic radiotherapy (RT) is known to be associated with chronic radiation proctitis (RP). However, the effects of intermediate radiation doses are unknown. We assessed the incidence of late clinical RP among patients with rectal cancer receiving intermediate-dose postoperative RT, as well as the role of early endoscopic abnormalities in predicting RP development. Methods: We retrospectively reviewed 153 patients with rectal cancer who received postoperative RT at a median dose of 54 Gy between 2005 and 2009 and who underwent endoscopic examination within 12 months thereafter. Endoscopic RP was assessed using the Vienna rectoscopy score (VRS). Late clinical RP toxicity was evaluated, as was its correlation with endoscopic RP. Results: All patients underwent an endoscopic examination at a median of 9 months after postoperative pelvic RT. Endoscopic RP was detected in 45 patients (29.4%); the predominant patterns were telangiectasia and congested mucosa. During the median 88-month follow-up period, 29 patients (19.0%) experienced late clinical RP; only 3 (2.0%) had Grade 3 or above. The VRS predicted the development of late clinical RP as well as its cumulative incidence (P < 0.001). Endoscopic evidence of telangiectasia was significantly associated with the development of late clinical RP (P < 0.001). Conclusions: Early endoscopic findings using VRS are useful for predicting the possibility of late clinical RP, although the incidences of severe cases were low. Patients with endoscopic abnormalities should be followed closely owing to their susceptibility to clinical RP.
Introduction
Late radiation proctitis (RP) is a common adverse event of pelvic radiotherapy (RT) that is administered to patients with a variety of malignancies, most often prostate and gynecologic tumors (1) (2) (3) . RP is of particular concern for patients with localized prostate cancer who receive high-dose RT, as shown in multiple dose escalation trials aimed at improving disease control (2, (4) (5) (6) (7) . Previous studies showed that rectal volumes receiving doses of 60 Gy (V60) or greater are consistently associated with the risk of Grade 2 or higher late rectal toxicity or bleeding (1, 6) . Conversely, the likelihood of developing RP has not been as extensively investigated in patients administered intermediate-dose pelvic RT, and data on the risk of late RP following rectal irradiation with doses below 60 Gy are limited. Since some studies have found that the V30-50 is significantly related to late RP and contributes to morbidity and poor quality of life (6, 8) , the risk related to late rectal morbidity for patients who receive intermediate-dose RT ought to be assessed. This includes patients with rectal cancer who are treated with postoperative RT doses of 45-60 Gy.
Endoscopic examination provides an accurate assessment of mucosal damage to the rectum, and is widely used for the evaluation and diagnosis of RP (9, 10) . Wachter et al. proposed the Vienna rectoscopy score (VRS) for endoscopic evaluation of the rectum, which is calculated based on five parameters: congested mucosa, telangiectasia, ulceration, stricture and necrosis (10) .
In this study, we aimed to confirm previously published data that endoscopic mucosal changes portend eventual late rectal toxicity in patients receiving pelvic RT (11) (12) (13) (14) . To that end, we investigated the incidence of late clinical RP among patients with rectal cancer receiving intermediate-dose postoperative RT as evaluated by using early endoscopy and the VRS.
Methods

Patient eligibility
A medical chart review was performed retrospectively for 176 consecutive patients with rectal cancer who underwent postoperative RT between January 2005 and December 2009 at our institution. The inclusion criteria were age 18 years or older, histological diagnosis of rectal cancer, treatment with surgery followed by postoperative RT with/without chemotherapy, and administration of colonoscopy within 12 months after RT. The patients excluded were those who did not complete postoperative RT (n = 1), had received previous pelvic RT (n = 14), underwent surgery with abdominoperineal resection (n = 8), and had inflammatory bowel disease, hemorrhoids or diverticulosis (n = 0). One hundred and fifty-three patients were included in this study.
Radiotherapy
Contrast-enhanced computed tomography (CT) with 5 mm thick slices was performed for RT planning. Each patient was instructed to maintain a full bladder in the prone position using a belly board with a bladder compression device during CT acquisition (15) . The CT image was imported into the Pinnacle planning system software version 9.4 (Philips Medical Systems, Cleveland, OH), following which the clinical target volume (CTV) and critical adjacent organs, including the bladder and small bowel, were delineated on each of the axial CT images by an experienced attending radiation oncologist. The CTV was defined as the postoperative tumor bed, presacral space and pelvic lymph nodes including the perirectal, internal iliac and obturator lymph node. Postoperative RT was delivered with three-dimensional conformal RT to the traditional whole pelvis with a median dose of 54 Gy (range, 50.4-59.4 Gy). Specifically, a median dose of 45 Gy (range, 41.4-45 Gy) was administered to the whole pelvis, followed by a boost with a median dose of 9 Gy (range, 5.4-14.4 Gy) to the operative tumor bed including the anastomotic site, residual rectum and perirectal tissue. Given this dosing regimen, our patients were considered to have undergone and leucovorin (20 mg/m 2 ) was administered to 78% of the patients.
The patients' characteristics and RT doses are shown in Table 1 .
Evaluation of early endoscopic RP based on endoscopic findings
Endoscopic RP was assessed during colonoscopy. At our institution, endoscopies were performed by trained digestive tract endoscopists with or without supervision. Additionally, a retrospective review of endoscopic findings was performed by an experienced digestive endoscopist (SJ Park) at the time of the study while blinded to any other patient information. Descriptions of endoscopic findings were focused on the five criteria of VRS including congested mucosa, telangiectasia, ulceration, stricture and necrosis; the final VRS ranged from 0 to 5 (10). In the current study, endoscopic RP was defined as rectal mucosal changes with a VRS of 1 or greater.
Evaluation of late clinical RP
Late clinical RP was assessed using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) criteria (16, 17) . The incidence of late clinical RP included all rectal toxicities of Grade 1 or higher. Patients were evaluated every 3 months during the first year after RT, every 6 months for the next 2 years, and annually thereafter. 
Results
Incidences of endoscopic and late clinical RP
All patients underwent endoscopic examination within a median period of 9 months (range, 5-12 months) after RT. Of the 153 patients, early endoscopic RP with VRS ≥1 was detected in 45 patients (29.4%). In terms of specific VRS criteria, congested mucosa was detected in 31 patients (20.2%); 42 patients (27.5%) showed telangiectasia, while ulcerations were observed in 12 patients (7.9%). Four patients (2.6%) experienced necrosis on the rectal wall. All detailed VRS distributions and endoscopic findings are shown in Table 2 .
The median follow-up was 88 months (range, 87-142 months), during which 28 patients died. The 5-and 10-year overall survival rates were 90.1% and 76.1%, respectively. Among all patients, late clinical RP as assessed by the RTOG/EORTC toxicity grade was detected in 29 patients (19.0%). Grade 1 was observed in 10 patients, Grade 2 in 16 and Grade 3 or above in 3 (2.0%); the latter included two who experienced rectal bleeding and required transfusion and argon plasma coagulation, and one who had rectal obstruction and underwent a transverse loop colostomy. Of the two patients who experienced Grade 3 rectal bleeding, 1 (who was 79 years of age) had multiple comorbidities including diabetes mellitus, hypertension and atrial fibrillation (Fig. 1) . The features of the three patients who experienced severe chronic RP are summarized in Supplementary Table 1 . Five other patients, who had Grade 2 RP, also experienced rectal bleeding and were managed with medical and conservative approaches.
Relationship between endoscopic abnormalities and occurrence of late clinical RP
During the follow-up period, patients with a VRS of 0, 1, 2, 3, 4 and 5 ultimately experienced clinical RP at rates of 3.7% (4/108), 12.5% (1/8), 47.1% (8/17), 50.0% (2/4), 71.4% (5/7) and 100% (9/9), respectively (P < 0.001). The development of clinical RP was significantly higher in patients who exhibited signs of endoscopic RP (58.1%) than in those who did not (3.7%) (P < 0.001). Additionally, clinical RP developed during a median period of 19 months (range, 6-61 month) after RT in patients with endoscopic RP, whereas those with no signs of endoscopic RP developed clinical RP within 80 months (range, 50-116 months). Furthermore, a significant correlation was observed between the VRS that indicated endoscopic RP and the grade of clinical RP; the Spearman correlation coefficient was 0.763 (P < 0.001; Fig. 2 ).
The development of clinical RP in patients with a VRS of 1-2 was significantly more frequent than in those with a VRS of 0 (Table 3) . Additionally, the incidence of clinical RP in patients with a VRS of 3-5 was higher than in those with a VRS of 0 (Table 3) . Upon further analysis to determine the impact of the endoscopic VRS on clinical late RP, late clinical rectal toxicity was more frequent in patients with a higher grade of endoscopic alterations than in those with lower grades (P < 0.001 for all; Table 4 ). Among these endoscopic findings, telangiectasia had a significant effect on the development of clinical RP on multivariable analysis (P < 0.001; Table 4 ).
Impact of endoscopic abnormalities on the cumulative incidence of late clinical RP
The 5-year cumulative incidence of late clinical RP was 15.3%. The 5-year cumulative incidence of developing late clinical RP increased in patients with VRS 3-5 compared to that in those with VRS 1-2 or VRS 0 (80.0% vs. 30.3% vs. 0%, respectively, P < 0.001; Fig. 3 ). On univariate analysis of the impact of the degree of endoscopic abnormality (as determined by VRS) on the cumulative incidence of late clinical RP, we found that patients with grades ≥2 mucosal abnormalities (or Grade 1 necrosis) had greater incidences of clinical rectal toxicity than patients with Grades <2 abnormalities (or Grade 0 necrosis) (P < 0.001 for all; Table 5 ). Moreover, the presence of telangiectasia (P = 0.001), congested mucosa (P = 0.006) and ulceration (P = 0.001) were revealed to be risk factors associated with an increased cumulative incidence of late clinical RP on multivariable analysis (Table 5 ).
Discussion
In this study, we identified an early rectal mucosal abnormality rate of 29% using colonoscopy in patients with rectal cancer receiving intermediate-dose postoperative RT. During a median follow-up period of 88 months, we observed that the incidences of late clinical RP of Grade 1 or higher and Grade 3 or higher were 19% and 2%, respectively. Furthermore, we revealed a close correlation between early endoscopic RP based on the VRS and late clinical RP based on the RTOG/EORTC grade, although the incidence of the former was significantly more frequent than that of the latter. Generally, late RP is diagnosed following clinical symptoms such as rectal pain, diarrhea, urgency, fecal incontinence and rectal bleeding, and is graded according to the RTOG/EORTC score (16) . Late RP is caused by pathologies such as obliterating endarteritis, abnormal new blood vessel formation, submucosal fibrosis and ischemia (17) . Therefore, it is reasonable to expect that clinical late RP should be associated with morphologic mucosal changes in the rectum such as mucosal atrophy, mucosal friability, capillary dilatation, ulceration and necrosis, either simultaneously or as delayed symptoms. Endoscopy might reveal subclinical signs of mucosal dysfunction. In previous studies, the VRS was confirmed to be a reliable predictor of radiation-induced mucosal changes (9, (11) (12) (13) . A study of 166 patients with prostate cancer who underwent RT showed that the VRS was highly correlated with the RTOG/EORTC score in terms of clinical rectal complications and endoscopic mucosal alterations (9) . Similarly, a study of 35 cervical cancer patients showed a positive correlation between the grade of late rectal toxicity and the VRS (13) . In our study, we showed that the risk of late RP in patients treated with intermediate-dose pelvic RT was increased if early A 79-year-old man was diagnosed with rectal adenocarcinoma, pT2N2M0, Stage III, after lower anterior resection. He had multiple comorbidities including diabetes mellitus, hypertension and atrial fibrillation. Owing to his old age, comorbidities and poor performance, he was administered postoperative radiotherapy (RT) alone in the form of three-dimensional conformal RT with a 45 Gy to the whole pelvis followed by a 9 Gy boost to the operative tumor bed. In 6 months after RT, he underwent a colonoscopy that showed a Vienna rectoscopy score of 4 (A), which consisted in Grade 3 congested mucosa, Grade 3 telangiectasia, Grade 2 ulcerations, Grade 1 stricture and no necrosis. After 1 month, he received argon plasma coagulation for active bleeding (B). endoscopic findings were abnormal. Furthermore, we noted that the higher the score of the endoscopic abnormality, the higher the risk of late RP development. Focusing on the impact of each type of endoscopic finding on clinical RP, Ippolito et al. reported that mucosal telangiectasia was significantly associated with the occurrence of clinical RP in prostate cancer patients administered high-dose RT (14) . Our data were consistent with their findings in that (1) the overall VRS was a strong predictor of clinical RP development, with all endoscopic findings being contributors to clinical RP on univariate analysis and (2) telangiectasia had a significant influence on the development of clinical RP and the cumulative incidence of clinical RP, according to the multivariable analysis results of each VRSrelated endoscopic parameter. Additionally, both congested mucosa and ulceration influenced the cumulative incidence of clinical RP.
The incidence rates of endoscopic RP vs. clinical late RP were different in our study. While endoscopy assesses the rectal mucosa status, late RP involves both mucosal neovascularization and submucosal fibrosis (18, 19) . Therefore, the endoscopic approach can miss changes in submucosal and muscularis propria layers that may also play an important role in the development of RP. Studies have suggested that the evolution of clinically visible injury was orchestrated by inflammatory responses not only in superficial mucosal tissue but also in supportive submucosal and muscular tissues (18) (19) (20) . In this regard, Cao et al. described the value of endorectal ultrasonography in diagnosing clinical RP, as this modality can clearly visualize morphologic changes in the submucosal, muscularis propria and perirectal tissues of the rectum (21) . In fact, there may be a difference in the times of onset of late radiation-induced toxicity depending on the manifestation of radiation-induced fibrogenesis (18) , also referred to as the radiation-induced fibroatrophic process (20) . Preclinical mucosal changes were observed in reactive tissues during the initial pre-fibrotic phase in the form of damaged endothelial cells as indicated by elevated cytokine or chemokine expression. Late clinical RP subsequently developed in unrepaired tissues, such as those that had undergone continuous remodeling as a result of the natural endothelial cell barrier loss combined with fibrosis-associated changes. In other words, the lower incidence of clinical RP than of endoscopic RP in our current study was attributed to the recovery of pre-fibrotic tissue owing to homeostatic tissue repair of damage caused by intermediate dose radiation. These findings indicate that radiotherapeutic injury is a complex process that occurs in organized tissues that are able to induce the tissue repair response mechanism to certain extents (18) (19) (20) 22) .
Chronic RP has no definite standard management. Since it produces a range of clinical symptoms, its occurrence was determined at the time of symptom onset, and the treatment approach depended on the nature and intensity of such symptoms. Patients with severe symptoms required therapeutic intervention. Pragmatic options for patients with late RP include oral drugs, rectal instillation, thermal therapy such as argon plasma coagulation, heater probe or laser, hyperbaric oxygen and surgery (3, 17, 23, 24) . In our study, only three patients (2.0%) experienced Grade 3 late clinical RP after intermediate-dose postoperative RT. Of these patients, two developed rectal bleeding that required both argon plasma coagulation All variables were entered into the binary logistic regression model with a backward stepwise method if P ≤ 0.10, and were removed at any point if P > 0.10. and transfusion, and the remaining patient who experienced rectal obstruction underwent a transverse loop colostomy. Furthermore, we observed a silent interval between the detection of preclinical signs and the actual clinical symptoms of late rectal damage after pelvic RT. Our findings implied that early subclinical rectal mucosa damage that fails to undergo physiologic repair may predispose the patient to subsequent complications such as late clinical RP. Therefore, it was important to identify factors that predict susceptibility to RP. Furthermore, patients with preclinical vasculogenesis or fibrogenesis may benefit from early intervention to promote the natural healing process and decrease the risk of clinical late toxicity. For example, antioxidant therapies (20) or normal-tissue response modifiers (18, 25) can be administered, especially as a recent investigation found that early-stage fibrotic processes are reversible (18) . In our study, it was necessary to examine patients presenting with symptoms of possible RP for early diagnosis and intervention. In the future, a late RP prevention approach should be devised through appropriate clinical trials (3).
In the absence of a clinical study for late RP in patients receiving intermediate-dose pelvic RT, our study showed the significance of early endoscopy in predicting late rectal toxicity in such patients. Additionally, the strength of our study lies in the homogeneity of the study population, which included patients with rectal cancer who were administered pelvic RT postoperatively with similar treatment volumes and total doses. However, a notable limitation was the lack of acquiring serial VRS of rectal mucosal changes (26) , including at baseline before RT and at the development of clinical late RP during follow-up. In particular, the absence of pre-RT baseline endoscopic evaluations resulted in our inability to determine whether mucosal abnormalities were caused by RT or by the so-called low anterior resection syndrome attributable to surgery (27) (28) (29) . Accordingly, it is important to note that the incidence of radiation-induced proctitis might have been overestimated because proctitis is also associated with vascular damage following chemotherapy, comorbidity, or other causes. Lastly, additional studies are required to determine the optimal timeframes for performing endoscopic assessments to predict clinical RP, as our study had a relatively low statistical power owing to its retrospective nature.
In conclusion, VRS-based endoscopic findings were useful predictors of the likelihood of late clinical RP in patients receiving intermediate-dose pelvic RT, although the incidence of severe late clinical RP was low. Careful follow-up of patients who show evidence of early endoscopic abnormalities may be required, as they are more susceptible to developing clinical RP.
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